search
Back to results

Electrocardiogram Clinical Validation Study

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
1-Lead ECG
12-Lead ECG
Sponsored by
Apple Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Atrial Fibrillation

Eligibility Criteria

22 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Individuals who are 22 years of age and older
  • Able to read, understand, and provide written informed consent
  • Willing and able to participate in the study procedures as described in the consent
  • Have a wrist circumference that fits within the band
  • Able to communicate effectively with and follow instructions from the study staff
  • For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening

Exclusion Criteria:

  • Physical disability that precludes safe and adequate testing
  • Mental impairment resulting in limited ability to cooperate
  • Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD)
  • Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable
  • Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening
  • Stroke or transient ischemic attack within 90 days of screening
  • Subjects taking rhythm control drugs
  • Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis on both wrists or over electrode attachment sites
  • Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands primarily used in wrist worn fitness devices
  • A history of abnormal life-threatening rhythms as determined by the investigator
  • Significant tremor that prevents subject from being able to hold still
  • Pregnant women: Women who are pregnant at the time of study participation
  • For subjects enrolled into the sinus rhythm population, they must not have any diagnosis of AF

Sites / Locations

  • QPS
  • BioClinicia- Orlando
  • BioClinica- The Villages
  • IQVIA
  • Health East

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Atrial fibrillation (AF)

Normal Sinus Rhythm (SR)

Arm Description

Patient with a known history of AF who are in AF at the time of study screening.

Patient with no known diagnosis of AF or other arrhythmia

Outcomes

Primary Outcome Measures

Number of Participants With Software's Rhythm Classification of SR in Agreement to a Physician's Interpretation of a Gold Standard 12-lead ECG
Specificity of rhythm classification
Number of Participants With Software's Rhythm Classification of AF in Agreement to a Physician's Interpretation of a Gold Standard 12-lead ECG
Sensitivity of rhythm classification

Secondary Outcome Measures

Number of Participants With Software's Ability to Produce a Clinically Equivalent Waveform in Agreement to a Gold Standard Lead 1 Reference
Number of ECGs that pass a visual overlay
Number of Participants With Software's Ability to Produce a Clinically Equivalent Waveform in Agreement to a Gold Standard Lead 1 Reference
Difference in R-wave amplitudes between the software and gold standard reference
Ease of Use
Average ease of use on a 1 (Unable to Use) to 5 (Easiest to Use) scale

Full Information

First Posted
February 27, 2018
Last Updated
November 19, 2020
Sponsor
Apple Inc.
Collaborators
Iqvia Pty Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT03492554
Brief Title
Electrocardiogram Clinical Validation Study
Official Title
Electrocardiogram Clinical Validation Study
Study Type
Interventional

2. Study Status

Record Verification Date
November 2020
Overall Recruitment Status
Completed
Study Start Date
March 12, 2018 (Actual)
Primary Completion Date
May 14, 2018 (Actual)
Study Completion Date
May 14, 2018 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Apple Inc.
Collaborators
Iqvia Pty Ltd

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to confirm the software's ability to create a Lead-1 electrocardiogram (ECG) that is clinically equivalent to a reference device. Also, to confirm a rhythm classification algorithm and its ability to detect and classify heart rhythms into two categories (Sinus Rhythm or Atrial Fibrillation) using a single Lead ECG.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
602 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Atrial fibrillation (AF)
Arm Type
Other
Arm Description
Patient with a known history of AF who are in AF at the time of study screening.
Arm Title
Normal Sinus Rhythm (SR)
Arm Type
Other
Arm Description
Patient with no known diagnosis of AF or other arrhythmia
Intervention Type
Other
Intervention Name(s)
1-Lead ECG
Intervention Description
All participants will record three single-lead ECGs
Intervention Type
Device
Intervention Name(s)
12-Lead ECG
Intervention Description
All participants will simultaneously record three 12-lead ECGs
Primary Outcome Measure Information:
Title
Number of Participants With Software's Rhythm Classification of SR in Agreement to a Physician's Interpretation of a Gold Standard 12-lead ECG
Description
Specificity of rhythm classification
Time Frame
1 Day
Title
Number of Participants With Software's Rhythm Classification of AF in Agreement to a Physician's Interpretation of a Gold Standard 12-lead ECG
Description
Sensitivity of rhythm classification
Time Frame
1 Day
Secondary Outcome Measure Information:
Title
Number of Participants With Software's Ability to Produce a Clinically Equivalent Waveform in Agreement to a Gold Standard Lead 1 Reference
Description
Number of ECGs that pass a visual overlay
Time Frame
1 Day
Title
Number of Participants With Software's Ability to Produce a Clinically Equivalent Waveform in Agreement to a Gold Standard Lead 1 Reference
Description
Difference in R-wave amplitudes between the software and gold standard reference
Time Frame
1 Day
Title
Ease of Use
Description
Average ease of use on a 1 (Unable to Use) to 5 (Easiest to Use) scale
Time Frame
1 Day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
22 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Individuals who are 22 years of age and older Able to read, understand, and provide written informed consent Willing and able to participate in the study procedures as described in the consent Have a wrist circumference that fits within the band Able to communicate effectively with and follow instructions from the study staff For subjects enrolled into the AF population, subjects must have a known diagnosis of AF and be in AF at the time of screening Exclusion Criteria: Physical disability that precludes safe and adequate testing Mental impairment resulting in limited ability to cooperate Subjects with a pacemaker or implantable cardioverter-defibrillator (ICD) Acute myocardial infarction (MI) within 90 days of screening or other cardiovascular disease that, in the opinion of the Investigator, increases the risk to the subject or renders data uninterpretable Acute pulmonary embolism, pulmonary infarction, or deep vein thrombosis within 90 days of screening Stroke or transient ischemic attack within 90 days of screening Subjects taking rhythm control drugs Symptomatic (or active) allergic skin reactions such as eczema, rosacea, impetigo, dermatomyositis or allergic contact dermatitis on both wrists or over electrode attachment sites Known sensitivity to medical adhesives, isopropyl alcohol, watch bands, or electrocardiogram (ECG) electrodes including known allergy or sensitivity to fluoroelastomer bands primarily used in wrist worn fitness devices A history of abnormal life-threatening rhythms as determined by the investigator Significant tremor that prevents subject from being able to hold still Pregnant women: Women who are pregnant at the time of study participation For subjects enrolled into the sinus rhythm population, they must not have any diagnosis of AF
Facility Information:
Facility Name
QPS
City
Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
BioClinicia- Orlando
City
Orlando
State/Province
Florida
ZIP/Postal Code
32806
Country
United States
Facility Name
BioClinica- The Villages
City
The Villages
State/Province
Florida
ZIP/Postal Code
32162
Country
United States
Facility Name
IQVIA
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66211
Country
United States
Facility Name
Health East
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55102
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Electrocardiogram Clinical Validation Study

We'll reach out to this number within 24 hrs